Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP, GC and Corp. Secretary | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,244 |
Ending reported balance
After 2026-02-16 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-02-13 · Grant · Acquired 14,804 · Balance 49,209 F1: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Row 2 · 2026-02-13 · Grant · Acquired 14,804 · Balance 64,013 F2: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Row 3 · 2026-02-13 · Exercise / conversion · Acquired 1,118 · Balance 65,131 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 4 · 2026-02-13 · Tax withholding · Disposed 12,792 · Balance 52,339 Row 5 · 2026-02-14 · Exercise / conversion · Acquired 1,851 · Balance 54,190 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 6 · 2026-02-14 · Tax withholding · Disposed 895 · Balance 53,295 Row 7 · 2026-02-16 · Exercise / conversion · Acquired 1,839 · Balance 55,134 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 8 · 2026-02-16 · Tax withholding · Disposed 890 · Balance 54,244 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-02-13 | Direct | 3,357 |
Reported balance
After 2026-02-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-13 · Exercise / conversion · Disposed 1,118 · Balance 3,357 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-02-14 | Direct | 1,851 |
Reported balance
After 2026-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-14 · Exercise / conversion · Disposed 1,851 · Balance 1,851 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2026-02-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-16 · Exercise / conversion · Disposed 1,839 · Balance 0 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F2: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
F5: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
F6: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · derivative · entry 11 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,839 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 890 | $74.73 | $66,509.70 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 8 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,244 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 7 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · derivative · entry 10 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,851 Underlying: Common Stock · 1,851 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 895 | $74.73 | $66,883.35 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 6 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,295 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 5 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · derivative · entry 9 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,357 Underlying: Common Stock · 1,118 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 12,792 | $74.73 | $955,946.16 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,339 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 14,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,013 F2 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 14,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,209 F1 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 17,510 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001225208-26-002013 · doc4.xml · derivative · entry 5 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,510 Underlying: Common Stock · 17,510 shares Expires 2036-02-12 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 7,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002013 · doc4.xml · derivative · entry 4 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,420 Underlying: Common Stock · 7,420 shares Expires 2030-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002013 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,886 Underlying: Common Stock · 1,442 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 488 | $74.12 | $36,170.56 |
DisclosureSEC source: 0001225208-26-002013 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,405 Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002013 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-006330 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,036 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,952 | $104.78 | $204,530.56 |
DisclosureSEC source: 0001225208-25-006330 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,451 Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-006330 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,826 | $106.42 | $513,582.92 |
DisclosureSEC source: 0001225208-25-005376 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,367 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024. Read SEC document |
| April 21, 2025 Filed Apr 22, 2025 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,826 | $95.09 | $458,904.34 |
DisclosureSEC source: 0001225208-25-004327 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,193 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 20:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,826 | $100.85 | $486,702.10 |
DisclosureSEC source: 0001225208-25-003606 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,019 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024. Read SEC document |
| February 21, 2025 Filed Feb 21, 2025 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,826 | $104.64 | $504,992.64 |
DisclosureSEC source: 0001225208-25-002170 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,845 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024. Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 11 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 484 | $106.11 | $51,357.24 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 6 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,671 Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 10 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,839 Underlying: Common Stock · 1,839 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 890 | $106.11 | $94,437.90 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,155 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 9 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,702 Underlying: Common Stock · 1,850 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 895 | $106.11 | $94,968.45 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,206 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 11,515 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 8 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 11,515 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 7 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Underlying: Common Stock · 4,475 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001789 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,328 Underlying: Common Stock · 1,442 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 424 | $105.77 | $44,846.48 |
DisclosureSEC source: 0001225208-25-001789 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,251 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001789 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 6,350 | $105.98 | $672,973.00 |
DisclosureSEC source: 0001225208-25-001680 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,233 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 14,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001680 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,583 F1 · kind: On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 6,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000202 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,456 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,991 | $89.32 | $177,836.12 |
DisclosureSEC source: 0001225208-25-000202 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,875 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000202 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-007198 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,036 Underlying: Common Stock · 4,036 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,952 | $76.41 | $149,152.32 |
DisclosureSEC source: 0001225208-24-007198 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,410 Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-007198 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,006 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-24-006324 · doc4.xml · derivative · entry 6 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,006 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 15,006 | $76.01 | $1,140,633.07 |
DisclosureSEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,326 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.7650 to $76.22, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 15,006 | $27.09 | $406,512.54 |
DisclosureSEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,037 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-24-006324 · doc4.xml · derivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,037 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 18,037 | $75.60 | $1,363,606.22 |
DisclosureSEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,326 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.505 to $75.74, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.